SAN DIEGO, CA--(Marketwired - Jun 12, 2014) - Adamis Pharmaceuticals Corp. (
Date: Monday, June 16, 2014
Time: 4:15pm ET (1:15pm PT)
Webcast link: http://public.viavid.com/index.php?id=109548
A webcast archive will be available approximately 30 minutes after the live webcast using the same link.
About Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. The company's current specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. The company's vaccine product candidates and cancer drug product candidates under research and development include TeloB-VAX, a cell-based therapeutic cancer vaccine and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.
Forward Looking Statements
This press release may contain forward-looking statements that relate to future events or our future results of operations or future financial performance, including, but not limited to the following statements: the ability to fund future product development and business operations; future revenues expected from any of the company's product candidates, assuming that they are developed and approved for marketing by the FDA and other regulatory authorities; our ability to complete any future acquisitions of products, product candidates or technologies; and the intellectual property protection that may be afforded by any patents or patent applications relating to the company's technology. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis' filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC's web site at http://www.sec.gov . Except as required by law, Adamis expressly disclaims any obligation to update any forward-looking statements.
Adamis Contacts Mark Flather Director, Investor Relations & Corporate Communications Adamis Pharmaceuticals Corp. Tel: 858- 412-7951 Email: mflather@adamispharma.com External Investor Relations Mark Gundy (972) 240-1873 markgundy@gmail.com
